Current Report Filing (8-k)
May 22 2019 - 3:38PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 21, 2019
INTELLIA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37766
|
|
36-4785571
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
40 Erie Street, Suite 130
Cambridge, Massachusetts
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (857)
285-6200
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.0001 per share
|
|
NTLA
|
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 or Rule
12b-2
of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07
|
Submission of Matters to a Vote of Security Holders
|
Intellia Therapeutics, Inc. (the Company) held its Annual Meeting of Stockholders on May 21, 2019 (the Annual Meeting). The
following is a summary of the matters voted on at that meeting.
|
a)
|
The stockholders of the Company elected Caroline Dorsa, Perry Karsen, and John M. Leonard, M.D. as class III
directors, for a three-year term ending at the annual meeting of stockholders to be held in 2022 and until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal. The results of the
stockholders vote with respect to the election of the class III directors were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Votes
For
|
|
|
Votes
Withheld
|
|
|
Broker
Non-
Votes
|
|
Caroline Dorsa
|
|
|
28,911,341
|
|
|
|
3,206,985
|
|
|
|
8,648,391
|
|
Perry Karsen
|
|
|
27,086,827
|
|
|
|
5,031,499
|
|
|
|
8,648,391
|
|
John M. Leonard, M.D.
|
|
|
29,071,594
|
|
|
|
3,046,732
|
|
|
|
8,648,391
|
|
|
b)
|
The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Companys
independent registered public accounting firm for the fiscal year ending December 31, 2019. The results of the stockholders vote with respect to such ratification were as follows:
|
|
|
|
|
|
Votes
For
|
|
Votes
Against
|
|
Abstain
|
40,597,519
|
|
119,999
|
|
49,199
|
|
c)
|
The stockholders of the Company approved, on an advisory basis, the compensation of the named executive
officers. The results of the stockholders vote with respect to the approval of the compensation of the named executive officers were as follows:
|
|
|
|
|
|
Votes
For
|
|
Votes
Against
|
|
Abstain
|
22,354,245
|
|
8,518,891
|
|
1,245,190
|
|
d)
|
The stockholders of the Company voted to hold an advisory vote on the compensation paid to its named executive
officers every year. The results of the stockholders vote to hold an advisory vote to determine the frequency of future stockholder advisory votes on the compensation paid to the Companys named executive officers were as follows:
|
|
|
|
|
|
|
|
1 year
|
|
2 years
|
|
3 years
|
|
Abstain
|
30,764,455
|
|
60,753
|
|
83,372
|
|
1,209,746
|
No other matters were submitted to or voted on by the Companys stockholders at the Annual Meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Intellia Therapeutics, Inc.
|
|
|
|
Date: May 22, 2019
|
|
By:
|
|
/s/ John M. Leonard
|
|
|
|
|
John M. Leonard, M.D.
President and Chief
Executive Officer
|
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024